Company Overview of Boston Therapeutics, Inc.
Boston Therapeutics, Inc. focuses on the development, manufacture, and commercialization of therapeutic drugs based on complex carbohydrate chemistry to address unmet medical needs in diabetes and inflammatory diseases. It offers SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. The company’s product pipeline includes BTI-320, a non-systemic chewable therapeutic compound, which has completed a Phase II clinical trial to reduce post-meal glucose elevation; IPOXYN, an injectable anti-necrosis drug candidate for the treatment of lower limb ischemia associated with diabetes; and OxyFex for use as an oxygen delivery agent in ve...
1750 Elm Street
Manchester, NH 03104
Founded in 2009
Key Executives for Boston Therapeutics, Inc.
Total Annual Compensation: $71.7K
Chief Financial Officer
Total Annual Compensation: $68.1K
Compensation as of Fiscal Year 2013.
Boston Therapeutics, Inc. Key Developments
Boston Therapeutics, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 7 14
Boston Therapeutics, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's revenue was $121,493 against $217,520 a year ago. Operating loss was $1,153,256 against $1,110,042 a year ago. Net loss was $1,159,926 or $0.03 basic and diluted per share against $1,116,863 or $0.04 basic and diluted per share a year ago.
For the nine months, the company's revenue was $186,711 against $242,974 a year ago. Operating loss was $3,917,493 against $2,287,122 a year ago. Net loss was $3,937,444 or $0.10 basic and diluted per share against $2,303,532 or $0.11 basic and diluted per share a year ago.
Boston Therapeutics, Inc. Reports Results from Phase IIb Clinical Study of BTI-320 in Patients with Type 2 Diabetes
Oct 9 14
Boston Therapeutics, Inc. reported results from its Phase IIb clinical study of BTI-320 in patients with type 2 diabetes conducted in the U.S. by Accumed Research Associates in Garden City, NY. SD-002 is one of three completed studies evaluating one group of overweight healthy subjects and two groups of type 2 diabetes patients' glycemic response to different doses of drug BTI-320. The SD-002 trial enrolled patients with type 2 diabetes diagnosed for at least one year and who are on stable dose of daily metformin for at least three months. The SD-002 patients were administered BTI-320 and metformin using a randomized, double-blind, placebo-controlled, dose-ranging, three-way cross-over study design. Patients' blood glucose was monitored using samples from their veins and their after-meal blood glucose levels were measured following a test meal. The data show BTI-320 was safe and well tolerated, with no adverse events reported. Of the 23 patients who completed the trial, 15 patients did not respond to the rice test meal for unexplained reasons. The remaining eight patients responded to BTI-320 with up to a 34% reduction in post meal blood glucose levels. Patients were given one to two BTI-320 tablets, one-third the dose of the University of Sydney trial and half of the dose of the Dartmouth Medical Center trial. The company has an ongoing Phase IIb trial in France where doses are two to four tablets. The BTI-320 Phase IIa trial at Dartmouth Medical Center showed that 45% of the type 2 diabetes patients studied exhibited a 40% reduction in post meal glucose levels from baseline. Most of these patients received multiple other glucose-lowering drugs and were given two to four BTI-320 tablets. The results from clinical study in healthy, but overweight, people at the University of Sydney in Australia showed that 100% of the people responded with the post meal blood glucose levels and insulin, on average, were respectively 32% and 24% lower. They were given three to six BTI-320 tablets.
Boston Therapeutics Appoints David S.H. Bell to its Medical Advisory Board
Oct 8 14
Boston Therapeutics, Inc. has appointed David S.H. Bell, MB, FACP, FACE, to its Medical Advisory Board. This increases the number of members of the Board to eight. Dr. Bell is an adjunct clinical professor of medicine at the University of Alabama at Birmingham School of Medicine where from 1980 to 2005 he served as a professor of medicine.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|